


Information exchange on combination therapies: what to share, what not to share?

The Belgian Competition Authority publishes a communication aimed at guiding pharmaceutical companies when exchanging information within the framework of the reimbursement procedure for combination therapies in order to comply with competition law.



Lists of examples, non-exhaustive

RECOMMENDATIONS

Establish barriers to prevent information about key competition parameters from being exchanged between competitors